Hanbeta®Bevacizumab Injection Instructions for Use

Update: 30 October, 2023

Hanbeta® (bevacizumab) is a biosimilar to Avastin® (bevacizumab) developed by Fosun Pharma, and is indicated for the treatment of metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, hepatocellular carcinoma, etc.


File format: PDF

Size: -

MD5 Checksum: 469A5D8C3D7712B661658CB6AE161EF2

Publication date: 30 October, 2023

Downloads: -

PDF Link: Hanbeta®Bevacizumab Injection Instructions for Use PDF

Also Manuals